Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.
Cue Biopharma(CUE.US)：2023年Q4财报实现营收182.1万美元，前值为15.1万美元，预期值为171万美元；每股收益为-0.28美元，前值为-0.37美元，预期值为-0.28美元。
Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.